Intravenous Remifentanil for Labor Analgesia
Information source: Nanjing Medical University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Labor Pain
Intervention: Hydromorphone (Drug); Remifentanil (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Nanjing Medical University Official(s) and/or principal investigator(s): XiaoFeng Shen, MD, Study Director, Affiliation: Nanjing Medical University
Summary
Labor analgesia is an essential health caring procedure for women. However, epidural
analgesia cannot be performed on all subjects for different contraindications, such as lower
platelet counter, back infection at the puncture site, and fear of epidural injection etc.
Therefore, intravenous analgesia is an alternative for such conditions. Given the influence
of intravenous administration of drugs on fetus, the drug selection is very important.
Remifentanil, a super-short efficacious opioid, can last for 3-4 minutes after injection,
which is similar in both maternal and fetal environment. Thus the fetus-associated side
effects would be less than other drugs. The investigators hypothesized that remifentanil
would be a superior intravenous drug used with patient-controlled technique for labor
analgesia.
Clinical Details
Official title: Remifentanil Intravenous Patient-controlled Labor Analgesia for Nulliparous Women
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Maternal Visual Analog Scale (VAS) rating of pain
Secondary outcome: Rate of cesarean deliveryRate of instrument-assisted delivery Indications of cesarean delivery Duration of analgesia Maternal satisfaction with analgesia Maternal oral temperature Use of oxytocin after analgesia Maximal oxytocin dose Breastfeeding success at 6 weeks after vaginal delivery Neonatal one-minute Apgar scale Neonatal five-minute Apgar scale Umbilical-cord gases analysis Neonatal sepsis evaluation Neonatal antibiotic treatment Incidence of maternal side effects
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
1. Nulliparous women
2. > 18 years and < 45 years
3. Spontaneous labor
4. Analgesia request
5. Epidural puncture contraindications
6. Tendency of bleeding
Exclusion Criteria:
1. Allergy to opioids, a history of the use of centrally-acting drugs of any sort,
chronic pain and psychiatric diseases records
2. Participants younger than 18 years or older than 45 years
3. Those who were not willing to or could not finish the whole study at any time
4. Using or used in the past 14 days of the monoamine oxidase inhibitors
5. Alcohol addictive or narcotic dependent patients were excluded for their influence on
the analgesic efficacy of the epidural analgesics
6. Subjects with a nonvertex presentation or scheduled induction of labor
7. Cervical dilation was 5. 0cm or greater before performing epidural puncture and
catheterization
8. Diagnosed diabetes mellitus and pregnancy-induced hypertension
9. Twin gestation and breech presentation
Locations and Contacts
Nanjing Maternal and Child Health Care Hospital, Nanjing, Jiangsu 210004, China
Additional Information
Starting date: July 2008
Last updated: September 17, 2009
|